Home › Agent Hub › Agent Tools › Part D coverage by drug › Zafirlukast
Agent Tools
Zafirlukast is a generic drug. What agents check before quoting it: how many 2026 Part D plans cover it, on which tier, with what restrictions and copays, by plan type, carrier and state.
In 2026, 5,278 of 5,496 Medicare Part D and Medicare Advantage drug plans (96%) list Zafirlukast on their formulary, across 312 of 328 formularies. The most common placement is tier 4 (2,828 plans, 53.6% of those covering it). 0 of the covering plans require prior authorization (0%), 0 step therapy and 3,064 a quantity limit.
1,050 covering plans charge a flat copay for a 30-day supply at a preferred retail pharmacy after the deductible — median $0, 533 of them $0; 4,228 charge coinsurance instead — median 25% of the drug's cost. Once a member's out-of-pocket drug spending reaches $2,100 in 2026, covered drugs cost $0 for the rest of the year.
2025: 5,527 of 5,631 plans covered it (98.2%); 2026: 5,278 of 5,496 (96%).
Of 4,368 plans offered in both years, 4 added it to the formulary and 32 dropped it.
Among plans covering it both years, 214 moved it to a higher tier and 34 to a lower one; 0 added prior authorization and 0 removed it.
Medicare Part D paid for 125,265 30-day fills of Zafirlukast in 2024 for about 15,513 enrollees, at an average total cost of $55.33 per 30-day fill (CMS Part D Prescribers by Geography and Drug, national).
Price Zafirlukast and the rest of a client's list on every plan in their county.
Estimate Zafirlukast costs by plan
Free tools for licensed insurance agents. Data from CMS public files; verify with plan documents before advising a client.
Counts are over every Medicare Advantage drug plan and stand-alone Part D plan in the CMS monthly formulary files, excluding employer plans. A plan counts as covering a drug when any strength or form of it is on the plan’s formulary; the tier, prior authorization, step therapy and quantity limit shown are the most favorable version on that formulary. Copays are for a 30-day supply at a preferred retail pharmacy after the deductible. This is a reference for licensed agents, not a plan recommendation; verify with the plan’s formulary before advising a client. Source: CMS Part D formulary files (release 09/16/2026). CMS formulary data.